Mercados españoles cerrados

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
16,07-0,63 (-3,77%)
Al cierre: 04:00PM EDT
15,75 -0,32 (-1,99%)
Después del cierre: 05:27PM EDT

Yahoo Finanzas España eliminará nuestros foros de Conversaciones el 15 de agosto. ¡Gracias por ser un miembro fiel de nuestra comunidad de Conversaciones de Finanzas!

Inicia sesión para publicar un mensaje.
  • K
    Kim
    $SRPT conversation
    FromSY investing:
    Cantor 2020 #biotech outlook

    Top picks:
    - Large-cap: $VRTX $AMGN
    - Mid-cap: $SRPT $ALNY
    - Small-cap: $TGTX $ICPT $GBT $AGIO
    - Favorite binary: $MYOK
  • h
    hairyknuckledragger
    $ICPT conversation
    From stocktwits forum:
    $ICPT
    a Stanford University abstract notes that liver transplant waitlist mortality among patients with PBC and decompensated cirrhosis is lower since Ocaliva approval compared to before Ocaliva approval.
  • T
    TRiMster3
    $ARWR conversation
    Just a note re NonAlcoholic SteatoHepatitis (if I type the Acronym the post won't go through for whatever reason). The FDA rejected $ICPT obeticholic acid (per @naturebiotech on t w i t t e r). The poster called it "another disappointment for a crowded field lettered with failures" - very poetic and more importantly shows what a great opportunity $ARWR to let the world know how it can solve problems not yet tackled by the many who have attempted and failed.
  • K
    Kim
    $SRPT conversation
    from Andrew Dunn:
    Top takeout targets, per new Credit Suisse investor survey:
    1. $CLVS
    2. $SRPT
    3. $ALDR
    4. $INCY
    5. $BMRN
    6. $GLPG
    7. $ALXN
    8. $IMMU
    9. $ICPT
    10. $VKTX
  • r
    rambogalaxyman
    $GALT conversation
    Galectin commences its adaptive phase 3 trial. Genfit flunks its phase 3 trial.
    Galectin commences its adaptive phase 3 trial. Genfit flunks its phase 3 trial.
    seekingalpha.com
  • h
    hairyknuckledragger
    $ICPT conversation
    From stocktwits forum:
    12/24/21, 06:39 AM
    $ICPT
    , $ 80 to $ 100 with positive Phase 3 results or $ 12 to $ 15 with failed trial. Unbelievably favorable Risk-Reward ratio. With 40 % short ratio. Load up guys.
  • K
    Kim
    $SRPT conversation
    From Dough;
    GS await $SRPT key 1Q19 event - MYO-101 Ph1/2 limb girdle muscular dystrophy biopsy data which expect to be positive based on gene expression levels of ~20%+ above baseline (measured by IHC) $ICPT NASH data is also expected imminently (1Q) – highlight favorably risk/reward HERE.
  • V
    Vs
    $BLUE conversation
    Sold other than 300 stock. They are profit only and will hold forever. Lately I am exiting most of my biotech.

    I still hold them in my IRA but no more regular account.
    Here is list of biotech I give up hope.
    1.> $AMRN
    2.> $BLUE
    3.> $MDGL
    4.> $ICPT
    5.> $PBYI
    6.> $CLVS (Only sold half before their disaster offering tank stock. HOlding to see if we get combo trial result boost. But may exit as well.)
    7.> NKTR (Half)
    8.> AERI ( Half)

    I am holding very large GILD (3000) and MRNA (3000). Sure I am shorting some high flyer so part of reason to sell is get buying power to I can hold or short more on those. Some day they will print solid profit but right now anything I touch on short, it start flying high and only stop if give up.
  • G
    GreenReaper
    $GREE conversation
    Most Shorted Stocks According To S3
    $CRTX – SI 58%
    $PPSI – SI 47%
    $GREE – SI 45%
    $IFMK – SI 45%
    $BYND – SI 39%
    $IMUN – SI 38%
    $BLNK – SI 37%
    $ICPT – SI 35%
    $BYSI – SI 33%
    $ESPR – SI 33%
    $BEEM – SI 33%
    $LMND – SI 33%
  • G
    GreenReaper
    $GREE conversation
    Stocks with the highest short interest
    $BFRI – SI 83%
    $CRTX – SI 55%
    $IMUN – SI 41%
    $LGVN – SI 38%
    $ICPT – SI 35%
    $SAVA – SI 35%
    $PRLD – SI 35%
    $BLNK – SI 35%
    $LMND – SI 35%
    $WEBR – SI 34%
    $RELI – SI 34%
  • S
    Sylvie L
    $ICPT conversation
    Wells Fargo lowering $ICPT PT to 113 the expert described the benefit of OCA in NASH as #underwhelming, well below that seen in the earlier FLINT study, and not sufficient to change practice, particularly given high pruritus rates.
  • A
    Arnaud
    $ICPT conversation
    JMP's Liisa Bayko (ranked 503 on 5.800 analysts) comments on $ICPT and PDUFA news; continues to recommend Intercept shares and maintains Outperform rating and **$200** price target
  • m
    mac
    $ICPT conversation
    Wells Fargo lowering $ICPT PT to 113 the expert described the benefit of OCA in NASH as #underwhelming, well below that seen in the earlier FLINT study, and not sufficient to change practice, particularly given high pruritus rates.
  • M
    MikeStocks
    $CNAT conversation
    "The phase 2 study has the surrogate and primary endpoint as HVPG - Hepatic venous pressure gradient. so if in Q4 2018 the phase 2 endpoint HVPG is met, then accelerated approval is possible without the need to run a phase 3 for approval."

    "the phase 2a pilot study for portal hypertension Conatus achieved a 92% response rate 11 out of 12 patients responding after only 4 weeks of treatment with emricasan given 25 mg twice daily."

    CNAT the next to report NASH Cirrhosis PH Phase 2b/3 at 5MG, 25MG, 50MG twice daily... if GOOD likely FDA approval... Trial data in or before Q4 2018.

    NASH $GALT $VKTX $GLMD $MDLG $ICPT
  • W
    WealthMastersClub1
    $GILD conversation
    The only company conducting a late stage clinical trial for the treatment of Refractory Ascites due to Liver Cirrhosis $NVS $NVO $ABBV $ICPT $TBIO
    https://www.youtube.com/watch?v=xxzTsexijPU&feature=youtu.be
  • J
    Jerry
    $ICPT conversation
    $ICPT met the end point but not much more in order to be a blockbuster they should showed much better results with 0 side effects $3.5B is way overpriced expect it to go down to around $2B.
  • K
    Kim
    $SRPT conversation
    From Dough:
    CITI SMid Biotech Catalyst Outlook
    72 pages $SRPT $FGEN $ICPT, $NVAX $SLDB $NERV $SNDX, $MDCO & more. CITI TOP 2 PICS $FGEN $SRPT 👍
  • B
    Bill
    $BFRI conversation
    Still at 83% so not much covering took place. Let's do some more frying.

    Stocks with the highest short interest
    $BFRI – SI 83%
    $CRTX – SI 55%
    $IMUN – SI 41%
    $LGVN – SI 38%
    $ICPT – SI 35%
    $SAVA – SI 35%
    $PRLD – SI 35%
  • D
    Devin
    $SLS conversation
    Bio Ph 2 & Ph 3 Data Readouts Feb

    $SWTX Ph 3
    $ADAG Ph 2
    $ICPT Ph 3
    $IMMP Ph 2
    $VERU Ph 2
    $DMAC Ph 2
    $KLDO Ph 2
    $MREO Ph 2
    $SLS Ph 2
    $CORT Ph 2
    $CRBP Ph 2
    $PRAX Ph 2
    $AMRN Ph 2
    $ZEAL Ph 3
    $CBAY Ph 2
    $ARVN Ph 2
    $TNXP Ph 3
    $FGEN Ph 2

    Catalyst Calendar => http://bpiq.com/fda-catalyst-calendar
  • K
    Kim
    $SRPT conversation
    from dough:
    CITI SMid Biotech Catalyst Outlook
    72 pages $SRPT $FGEN $ICPT, $NVAX $SLDB $NERV $SNDX, $MDCO & more. CITI TOP 2 PICS $FGEN $SRPT